life scienc tool diagnost
oper guidanc light
ep ahead consensu mck adj ep
handili beat estim better revenu profit
includ one-tim benefit factor line ad
boost ep guidanc higher
midpoint reflect weaker profit experi europ off-set lower
corpor expens fulli reflect beat lift
ep beat off-set weaker top-line
profit experi balanc year
revenu profit prevail revenu exceed
estim stronger us pharma/spec experi vs estimate
weaker eu pharma experi vs estimate well medsurg
vs estimate partial offset gross margin declin
bp bp plan meanwhil lower admin expens bp y/i
bp better plan help off-set ebitda margin deterior
bp bp ahead estim importantli us dist oper profit
improv nice ahead view use million
cash complet billion share repurchas reserv stand
billion net debt/ltm ebitda
reiter neutral share ytd vs
momentum share may eas despit latest oper upsid
impress core us pharma experi updat guidanc fulli
reflect meaning beat said top-line profit target
larg unchang segment except lower
target profit trend europ continu weak uk retail pharmaci
environ punt contempl implic new drug
import initi releas trump administr today
would allow import certain drug canada
acknowledg risk factor potenti greater drug price headwind well
opportun current sizeabl canadian busi
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
deliv pharmaceut medic suppli
healthcar inform technolog custom
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
better fundament perform sentiment could drive upsid
target price blue sky scenario
weaker fundament perform sentiment could lead
downsid versu target price grey sky scenario
 close
compani mention price
